AAAAAA

   
Results: 1-7 |
Results: 7
Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft
Authors: di Grazia, C Raiola, AM Van Lint, MT Lamparelli, T Gualandi, F Berisso, G Bregante, S Dominietto, A Mordini, N Bruno, B Frassoni, F Bacigalupo, A
Citation: C. Di Grazia et al., Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft, HAEMATOLOG, 86(6), 2001, pp. 646-651
Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose
Authors: Dominietto, A Raiola, AM van Lint, MT Lamparelli, T Gualandi, F Berisso, G Bregante, S Frassoni, F Casarino, L Verdiani, S Bacigalupo, A
Citation: A. Dominietto et al., Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose, BR J HAEM, 112(1), 2001, pp. 219-227
Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study
Authors: Bacigalupo, A Lamparelli, T Gualandi, F Bregante, S Raiola, A di Grazia, C Dominietto, A Romagnani, C Occhini, D Frassoni, F van Lint, MT
Citation: A. Bacigalupo et al., Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study, BLOOD, 98(10), 2001, pp. 3174-3175
Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin
Authors: Lamparelli, T van Lint, MT Gualandi, F Raiola, AM Barbanti, M Sacchi, N Ficai, G Ghinatti, C Bregante, S Berisso, G Dominietto, A Di Grazia, C Bruno, B Sessarego, M Casarino, L Verdiani, S Bacigalupo, A
Citation: T. Lamparelli et al., Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin, BONE MAR TR, 26(12), 2000, pp. 1305-1311
Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support
Authors: Boccadoro, M Omede, P Dominietto, A Palumbo, A Bringhen, S Giaretta, F Ortolano, B Triolo, S Pileri, A
Citation: M. Boccadoro et al., Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support, BONE MAR TR, 25(1), 2000, pp. 25-29
An analysis of which subgroups of multiple myeloma patients, divided according to beta(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy
Authors: Boccadoro, M Tarella, C Palumbo, A Argentino, C Triolo, S Dominietto, A Callea, V Lauta, VM Molica, S Musto, P Marmont, F Gianni, AM Pileri, A
Citation: M. Boccadoro et al., An analysis of which subgroups of multiple myeloma patients, divided according to beta(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy, HAEMATOLOG, 84(10), 1999, pp. 905-910
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients
Authors: Palumbo, A Triolo, S Argentino, C Bringhen, S Dominietto, A Rus, C Omede, P Tarella, C Pileri, A Boccadoro, M
Citation: A. Palumbo et al., Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients, BLOOD, 94(4), 1999, pp. 1248-1253
Risultati: 1-7 |